Considerations of Hilar Cholangiocarcinoma. Surg. Oncol. Clin. N.,Am Cholangiocarcinoma. Surg. Oncol. Clin. N. . .. , 28(4) : 601-617.
Botticelli A,Cirillo A,Strigari L,Valentini F,Cerbelli B,Scagnoli S,Cerbelli E,Zizzari IG,Rocca CD,D'Amati G,Polimeni A,Nuti M,Merlano MC,Mezi S,Marchetti P .2021 .Anti-PD-1 and anti-PD-L1 in head and neck cancer: A network meta-analysis. Front Immunol, 12 : 705096.
Budimir N,Thomas GD,Dolina JS,Salek-Ardakani S .2022 .Reversing T-cell exhaustion in cancer: Lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol. Res., 10(2) : 146-153.
Edeline J,Touchefeu Y,Guiu B,Farge O,Tougeron D,Baumgaertner I,Ayav A,Campillo-Gimenez B,Beuzit L,Pracht M,Lièvre A,Le Sourd S,Boudjema K,Rolland Y,Boucher E,Garin E .2020 .Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol., 6(1) : 51-59.
Elvevi A,Laffusa A,Scaravaglio M,Rossi RE,Longarini R,Stagno AM,Cristoferi L,Ciaccio A,Cortinovis DL,Invernizzi P,Massironi S P .2022 .Clinical treatment of cholangiocarcinoma: An updated comprehensive review. , 27(5) : 100737.
Forde PM,Chaft JE,Smith KN,Anagnostou V,Cottrell TR,Hellmann MD,Zahurak M,Yang SC,Jones DR,Broderick S,Battafarano RJ,Velez MJ,Rekhtman N,Olah Z,Naidoo J,Marrone KA,Verde F,Guo H,Zhang J,Caushi JX,Chan HY,Sidhom JW,Scharpf RB,White J,Gabrielson E,Wang H,Rosner GL,Rusch V,Wolchok JD,Merghoub T,Taube JM,Velculescu VE,Topalian SL,Brahmer JR,Pardoll DM .2018 .Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med, 378(21) : 1976-1986.
Goyal L,Kongpetch S,Crolley VE,Bridgewater J .2021 .Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat. Rev., 95 : 102170.
Kelley RK,Ueno M,Yoo C,Finn RS,Furuse J,Ren Z,Yau T,Klümpen HJ,Chan SL,Ozaka M,Verslype C,Bouattour M,Park JO,Barajas O,Pelzer U,Valle JW,Yu L,Malhotra U,Siegel AB,Edeline J,Vogel A,Investigators A .2023 .Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. , 401(10391) : 1853-1865.
Klein O,Kee D,Nagrial A,Markman B,Underhill C,Michael M,Jackett L,Lum C,Behren A,Palmer J,Tebbutt NC,Carlino MS,Cebon J .2020 .Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol., 6(9) : 1405-1409.
Kong Y,Zhao X,Xu M,Pan J,Ma Y,Zou L,Peng Q,Zhang J,Su C,Xu Z,Zhou W,Peng Y,Yang J,Zhou C,Li Y,Guo Q,Chen G,Wu H,Xing P,Zhang L P .2022 .PD-1 inhibitor combined with radiotherapy and gm-csf (prag) in patients with metastatic solid tumors: An open-label phase II study. , 13 : 952066.
Lee JW,Zhang Y,Yoshizawa T,Argani P,Wood LD,Oshima K LD .2022 .Cancerization of ducts in hilar cholangiocarcinoma. Virchows, 481(2) : 1-10.
Li Q,Han J,Yang Y,Chen Y Y .2022 .PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol, 13 : 1070961.
Marabelle A,Le DT,Ascierto PA,Di Giacomo AM,De Jesus-Acosta A,Delord JP,Geva R,Gottfried M,Penel N,Hansen AR,Piha-Paul SA,Doi T,Gao B,Chung HC,Lopez-Martin J,Bang YJ,Frommer RS,Shah M,Ghori R,Joe AK,Pruitt SK,Diaz LA,Study LA,Clin LA .2020 .Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-. , 38(1) : 1-10.
Quinn LM,Haldenby S,Antzcak P,Fowler A,Bullock K,Kenny J,Gilbert T,Andrews T,Diaz-Nieto R,Fenwick S,Jones R,Costello-Goldring E,Poston G,Greenhalf W,Palmer D,Malik H,Goldring C H .2023 .Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Sci. Rep, 13(1) : 6681.
Rizvi S,Khan SA,Hallemeier CL,Kelley RK,Gores GJ .2018 .Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol., 15(2) : 95-111.
Soares KC,Jarnagin WR .2021 .. The Landmark Series: Hilar Cholangiocarcinoma. Ann. Surg, 28(8) : 4158-4170.
Xia T,Li K,Niu N,Shao Y,Ding D,Thomas DL,Jing H,Fujiwara K,Hu H,Osipov A,Yuan C,Wolfgang CL,Thompson ED,Anders RA,He J,Mou Y,Murphy AG,Zheng L AG .2022 .Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J. Hematol. Oncol., 15(1) : 37.
Zhang MY,Luo M,Wang JP .2022 .FXR expression in rats of hilar cholangiocarcinoma. Sci. Rep, 12(1) : 8741.
Zhang MY,Wang JP,He K,Xia XM .2021 .Bsep expression in hilar cholangiocarcinoma of rat model. Sci. Rep, 11(1) : 2861.
Zhao Q,Chen Y,Du S,Yang X,Chen Y,Ji Y,Zeng Z Y .2021 .Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: Reflection from four cases. Cancer Biol, 22(3) : 175-183.